Raysearch Laboratories Trades Lower Amid Shift in Short‑Selling Activity

Raysearch Laboratories AB (RAY‑B.ST) slid 3.4 % over the 24‑hour period that concluded at 07:11 PM Central Europe on Thursday, 22 October. The stock is presently trading at roughly SEK 193.8 on major exchanges. With a market cap of SEK 6.3 billion and 33.5 million shares outstanding, the company saw SEK 27.5 million worth of shares change hands in the past day—an indicator of moderate liquidity.

The latest figures show the 200‑day simple moving average at SEK 194.85, placing the current price just below this long‑term benchmark. In a year‑long view, Raysearch’s peak price was SEK 264.5 on 11 July 2025, while the 52‑week low was SEK 153.1 on 16 July 2026. Over the past month, the shares have risen 11.19 %, underscoring the company’s upward trajectory despite the recent dip.

Shareholding Structure and Short‑Selling Dynamics

A notable development in the firm’s ownership landscape is the reduction of Tudor Capital’s short‑selling position to less than half a percent of the company’s capital, effectively removing Tudor from the roster of public short sellers. Five other short sellers remain active, accounting for roughly ten percent of total short‑selling activity. Analysts point out that the current short interest, combined with expectations for the forthcoming November earnings report, could precipitate significant price volatility. Historical quarterly releases have often triggered sizeable swings, and recent commentary suggests that upside potential may be capped while downside risk remains pronounced.

Clinical Innovation and Market Position

Raysearch’s continued involvement in advanced radiotherapy trials—most prominently the C‑FLASH‑01 study—remains a focal point for investors and industry observers alike. The company’s flagship product, RayStation, is a comprehensive treatment‑planning system that supports a spectrum of modalities, including VMAT, IMRT, 3D‑CRT, tomotherapy, and stereotactic planning, among others. Complementary solutions such as RayPlan and RayCare further extend the company’s portfolio into machine‑learning‑driven oncology information systems. These offerings, coupled with training courses and robust customer support, position Raysearch as a key player in the global radiation‑therapy market.

Contextual Movements in Peer Stocks

The 24‑hour performance of several peer companies provides additional context for Raysearch’s market environment:

  • Xvivo Perfusion (XVIVO.ST) decreased 1.31 % to SEK 223.4, maintaining a market cap of SEK 7.2 billion. The firm reported a quarter‑over‑quarter sales increase, driven by its thoracic and abdominal lines, while service revenue contracted. Strong gross margins and improved operating income outpaced analyst expectations, though substantial R&D outlays impacted total cash flow. Notably, Xvivo secured both a CE certificate and FDA approval for its Heart Assist Transport System, signaling regulatory progress.

  • Svolder (SVOL-B.ST) gained 2.14 % to SEK 62.1, with a market cap of SEK 6.4 billion. The company was named a representative on the nomination committee for Arla Plast AB’s 2027 AGM, with Lars Kvarnsund leading the committee. No further operational details were disclosed.

  • Gruvaktiebolaget Viscaria (VISC.ST) edged down 0.32 % to SEK 17.9, holding a market cap of SEK 7.1 billion. The firm announced an upcoming presentation of its Q3 2026 financial results, which will detail operating performance and guidance for the remaining year.

  • Investment Oresund (ORES.ST) declined 1.36 % to SEK 142.4, with a market cap of SEK 6.6 billion and a price‑to‑earnings ratio of 5.28.

  • Truecaller (TRUE-B.ST) climbed 2.24 % to SEK 25.38, maintaining a market cap of SEK 7.5 billion and a price‑to‑earnings ratio of 33.

These movements illustrate a market that is broadly dynamic, with sectors ranging from medical technology to consumer software displaying varied performance trends.

Forward‑Looking Outlook

Analysts emphasize the importance of the forthcoming November earnings report for Raysearch Laboratories. While the company’s product suite and clinical trial engagements provide a solid foundation, the elevated short‑interest level and the inherent volatility associated with quarterly disclosures suggest that investors should remain vigilant. The potential for upside appears limited by the current valuation, yet the downside risk is not negligible, particularly in a landscape where clinical outcomes and regulatory approvals can swiftly alter market sentiment.

In sum, Raysearch Laboratories stands at a crossroads: its robust technological offerings and active clinical trial portfolio position it favorably, but recent market dynamics and shareholder activity underscore the need for careful monitoring as the company approaches its next earnings cycle.